This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.

Further information can be found on our website under Clincial Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332

There are currently 24 open trials. In 67 locations

What is a Clinical Trial?

Step 3: View Details

Trial Title:

Venetoclax in combination with bortezomib and dexamethasone


Bortezomib (Velcade®)

Myeloma stage:

Relapsed, Refractory

Trial phase:




This trial is determining whether combining a drug called venetoclax with bortezomib (Velcade) and dexamethasone is more effective than bortezomib and dexamethasone alone for relapsed and/or refractory myeloma patients.

Venetoclax belongs to a class of drugs known as Bcl-2 inhibitors.




Blackpool Victoria Hospital, Blackpool;
Kent and Canterbury Hospital, Canterbury;
Leicester Royal Infirmary, Leicester;
University College Hospital, London;
Manchester Royal Infirmary;
Queen’s Hospital, Romford;
St Bartholomew's Hospital, London;
King's College Hospital, London;
The Christie Hospital, Manchester;
City Hospital, Nottingham;
New Cross Hospital, Wolverhampton

Who can enter the study?

Who can enter the study?:

  • Relapsed and/or refractory myeloma patients who have had at least one but no more than three previous lines of treatment and who now require further treatment
  • Patients who have previously received and responded well to bortezomib
What's involved?

What's involved?:

Patients are randomised to receive either venetoclax, bortezomib and dexamethasone or bortezomib and dexamethasone.  Venetoclax and dexamethasone are given orally while bortezomib is given as a subcutaneous injection.

Patients are required to attend outpatient clinics for regular checkups and blood tests.

Clinical Information

Clinical Information
(for Medical Professionals):

This trial is evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in relapsed and/or refractory myeloma patients who are considered sensitive or naive to proteasome inhibitors.

For more information, click here

Do you want to talk to someone? Call our myeloma Infoline